Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, China.
Beijing Key Laboratory of Geriatric Cognitive Disorders, Beijing, China.
CNS Neurosci Ther. 2024 Feb;30(2):e14581. doi: 10.1111/cns.14581.
We aimed to explore the role and molecular mechanism of polygalacic acid (PA) extracted from traditional Chinese medicine Polygala tenuifolia in the treatment of Alzheimer's disease (AD).
The network pharmacology analysis was used to predict the potential targets and pathways of PA. Molecular docking was applied to analyze the combination between PA and core targets. Aβ42 oligomer-induced AD mice model and microglia were used to detect the effect of PA on the release of pro-inflammatory mediators and its further mechanism. In addition, a co-culture system of microglia and neuronal cells was constructed to assess the effect of PA on activating microglia-mediated neuronal apoptosis.
We predict that PA might regulate inflammation by targeting PPARγ-mediated pathways by using network pharmacology. In vivo study, PA could attenuate cognitive deficits and inhibit the expression levels of inflammation-related factors. In vitro study, PA can also decrease the production of activated microglia-mediated inflammatory cytokines and reduce the apoptosis of N2a neuronal cells. PPARγ inhibitor GW9662 inversed the neuroprotective effect of PA. Both in vivo and in vitro studies showed PA might attenuate the inflammation through the PPARγ/NF-κB pathway.
PA is expected to provide a valuable candidate for new drug development for AD in the future.
本研究旨在探讨从传统中药远志中提取的远志酸(PA)在治疗阿尔茨海默病(AD)中的作用和分子机制。
采用网络药理学分析预测 PA 的潜在靶点和通路。应用分子对接分析 PA 与核心靶点的结合情况。采用 Aβ42 寡聚体诱导的 AD 小鼠模型和小胶质细胞,检测 PA 对促炎介质释放的影响及其作用机制。此外,构建小胶质细胞和神经元细胞共培养系统,评估 PA 对激活小胶质细胞介导的神经元细胞凋亡的作用。
通过网络药理学预测,PA 可能通过靶向 PPARγ 介导的通路来调节炎症。体内研究表明,PA 可改善认知功能障碍,并抑制炎症相关因子的表达水平。体外研究表明,PA 还可减少激活的小胶质细胞介导的炎症细胞因子的产生,减少 N2a 神经元细胞的凋亡。PPARγ 抑制剂 GW9662 逆转了 PA 的神经保护作用。体内和体外研究均表明,PA 可能通过 PPARγ/NF-κB 通路减轻炎症反应。
PA 有望为 AD 的新药研发提供有价值的候选药物。